Definium Therapeutics, Inc.
DFTX
Rang in aandelen
#3484
Definium Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm... Definium Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to developing innovative therapeutic solutions for various brain health and neurological disorders. Its pipeline features key experimental drug candidates like MM120, which is currently undergoing Phase 3 clinical trials for generalized anxiety disorder (GAD) and attention deficit hyperactivity disorder (ADHD). Another significant compound, MM402 – an R-enantiomer of 3,4-methylenedioxymethamphetamine – is in Phase 1 trials, targeting the fundamental symptoms of autism spectrum disorder. The company maintains its headquarters in New York, New York.
Aandeelprijs
$35.98
Marktkapitalisatie
$4.83B
Verandering (1 dag)
1.39%
Verandering (1 jaar)
239.49%
Land
US
Handel Definium Therapeutics, Inc. (DFTX)
Categorie
Healthcare
Koersgeschiedenis voor Definium Therapeutics, Inc. (DFTX)
Hoogste slotkoers: $10.57 op 2024-04-01
Laagste slotkoers: $4.87 op 2020-03-01
Laagste slotkoers: $4.87 op 2020-03-01
Koersgeschiedenis van Definium Therapeutics, Inc. van 2020 tot 2026
Jaarlijkse koersprestatie
| Jaar | Prestaties |
|---|---|
| 2024 | 205.04% |
| 2023 | 33.53% |
| 2022 | -89.94% |
| 2021 | -40.17% |
| 2020 | 0.00% |
Aandelenkoers van vergelijkbare bedrijven of concurrenten
| Bedrijf | Aandelenkoers | Verandering 1jr% | Land |
|---|---|---|---|
| $535.37 | 25.54% |
US
|
|
| $185.00 | 589.01% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $291.76 | 2.51% |
BE
|
|
| $885.21 | 8.73% |
NL
|
